Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Fragment-based Hit Discovery for the Epigenetic Target BRD3

Sygnature Discovery has designed and synthesised a proprietary fragment librarywith a high degree of
novelty that covers awide range of chemical space. Comprised of over 900 compounds,majority are not
commercially available, the librarywas designed using the‘rule of 3’as a guideline andwith a strong
emphasis on diversity. To demonstrate its effectiveness in fragment-based drug discovery, the librarywas screened against an
epigenetic targetwith little previous literature on drug discovery, Bromodomain-containing protein 3 (BRD3,
also known as RING3L).

Download Poster

Poster download form with organisation field
Invalid email address provided.
Please only use your business email address.